Literature DB >> 15561156

Health care transitions for adolescents with congenital heart disease: patient and family perspectives.

Elizabeth M Tong1, Susan Kools.   

Abstract

Advances in medical management and surgical treatment have improved the longevity and quality of life for patients with CHD. However, meeting the health care needs of this growing population has not kept pace with the advances in technology. Adolescents with CHD are caught between both childhood and adulthood and pediatric and adult cardiology. As health care providers develop strategies to meet the special health care transition needs of this group, patient and family perspectives must be understood and included in the transition plan if one is to develop meaningful interventions. Assessment and recognition of the developmental changes occurring for both adolescents and their families and the impact of chronic illness on these changes are critical if transition is to be successful. Expectations,individual biases, and negative stereotypes need to be recognized and reframed if one is to establish an empathetic, positive, and trusting relationship with patients and their families. Greater sensitivity also needs to be given to the shifting roles, responsibilities, and inherent losses that occur with transition. Nurses have a key role in guiding patients and families toward adult, independent self-care by helping them identify and use their talents and resources as they move toward achieving their goals and dreams for the future.

Entities:  

Mesh:

Year:  2004        PMID: 15561156     DOI: 10.1016/j.cnur.2004.07.011

Source DB:  PubMed          Journal:  Nurs Clin North Am        ISSN: 0029-6465            Impact factor:   1.208


  6 in total

1.  Transition and transfer from pediatric to adult care of young adults with complex congenital heart disease.

Authors:  Alison Knauth Meadows; Valerie Bosco; Elizabeth Tong; Susan Fernandes; Arwa Saidi
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

Review 2.  From adolescents to adults with congenital heart disease: the role of transition.

Authors:  Pamela Moceri; Eva Goossens; Sebastien Hascoet; Carine Checler; Béatrice Bonello; Emile Ferrari; Philippe Acar; Alain Fraisse
Journal:  Eur J Pediatr       Date:  2015-05-10       Impact factor: 3.183

3.  Attitude toward and current practice of transfer and transition of adolescents with congenital heart disease in the United States of America and Europe.

Authors:  Deborah Hilderson; Arwa S Saidi; Kristien Van Deyk; Amy Verstappen; Adrienne H Kovacs; Susan M Fernandes; Mary M Canobbio; Desiree Fleck; Alison Meadows; Rachel Linstead; Philip Moons
Journal:  Pediatr Cardiol       Date:  2009-04-14       Impact factor: 1.655

4.  Health-related quality of life in children with congenital heart disease aged 5 to 7 years: a multicentre controlled cross-sectional study.

Authors:  Hamouda Abassi; Helena Huguet; Marie-Christine Picot; Marie Vincenti; Sophie Guillaumont; Annie Auer; Oscar Werner; Gregoire De La Villeon; Kathleen Lavastre; Arthur Gavotto; Pascal Auquier; Pascal Amedro
Journal:  Health Qual Life Outcomes       Date:  2020-11-12       Impact factor: 3.186

5.  Health-related quality of life in Italian children and adolescents with congenital heart diseases.

Authors:  Giulia Amodeo; Benedetta Ragni; Giulio Calcagni; Simone Piga; Salvatore Giannico; Marie Laure Yammine; Fabrizio Drago; Marta Luisa Ciofi Degli Atti; Angela Rossi; Simona De Stasio; Teresa Grimaldi Capitello
Journal:  BMC Cardiovasc Disord       Date:  2022-04-15       Impact factor: 2.174

6.  The CHIP-Family study to improve the psychosocial wellbeing of young children with congenital heart disease and their families: design of a randomized controlled trial.

Authors:  Malindi van der Mheen; Ingrid M van Beynum; Karolijn Dulfer; Jan van der Ende; Eugène van Galen; Jorieke Duvekot; Lisette E Rots; Tabitha P L van den Adel; Ad J J C Bogers; Christopher G McCusker; Frank A Casey; Willem A Helbing; Elisabeth M W J Utens
Journal:  BMC Pediatr       Date:  2018-07-12       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.